Avigena and Mass General Brigham’s LMM Launch Landmark Genomic Collaboration for the MENA Region

Boston, MA — November 2025 — Avigena, a U.S.-based genomic medicine company, has
entered a landmark collaboration with the Laboratory for Molecular Medicine (LMM) at
Mass General Brigham, marking the first introduction of advanced predictive and preventive
genomic testing tailored to Middle East and North Africa (MENA) populations.
Through this partnership, Avigena will deploy LMM’s state-of-the-art genomic technologies to
enable earlier risk prediction, precision prevention, and scalable population health impact across
the region.

The agreement was finalized during a strategic visit to Boston, where Avigena Co-Founders
Fadi Bitar and Akl Fahed met with Matthew Lebo, Chief Laboratory Director of LMM and
Harvard Medical School faculty, and Lisa Marie Mahanta, Director of Clinical Operations at
LMM.

The collaboration underscores a shared mission to expand access to world-class genomic science
and advance precision prevention across the MENA region.